Patent US5378475A successfully refreshed from Google Patents.
US5378475A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release drug delivery devices
Assignee: KENTUCKY RESEARCH FOUNDATION A CORP OF, University of
•
Filing: 1991-02-21
•
Granted: 1995-01-03
•
Expires: 2011-02-21
Abstract
Abstract A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir comprising the effective agent; a first coating layer, which is essentially impermeable to the passage of the effective agent; and a second coating layer, which is permeable to the passage of the effective agent. The first coating layer covers at least a portion of the inner core; however, at least a small portion of the inner core is not coated with the first coating layer. The second coating layer essentially completely covers the first coating layer and the uncoated portion of the inner core.
Inventors
- 👤 Thomas J. Smith
- 👤 Paul Ashton
- 👤 Paul A. Pearson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 17:52
CPC Classifications
A; A61; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61K9/48; A61K9/50; A61K9/5073; A61P; A61P27/00; A61P27/02; A61P31/00; A61P31/12; A61K9/20; A61K9/28; A61K9/2806; A61K9/2833; A61K9/284; A61K9/5005; A61K9/5021; A61K9/5026
Claims Analysis
Total Claims: 42
Claim 1
Independent Claim
188 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising: administering a sustained release drug delivery system to a mammalian organism in need of such treatment, said drug delivery system comprising; (1) an inner core or reservoir comprising an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect, (2) a first polymer coating layer, said first coating layer essentially impermeable to the passage of said agent, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first coating layer, and (3) a second polymer coating layer permeable to the passage of said agent, wherein said second polymer coating layer essentially completely covers said first polymer coating layer and the uncoated portion of the inner core, whereby said agent is able to pass through said second polymer coating layer in a controlled manner wherein said first polymer coating layer and said second polymer coating layer are essentially insoluble and inert in body fluids.
Claim 2
Independent Claim
188 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising: administering a sustained release drug delivery system to a mammalian organism in need of such treatment, said drug delivery system comprising; (1) an inner core or reservoir comprising an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect, (2) a first polymer coating layer, said first coating layer essentially impermeable to the passage of said agent, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first coating layer, and (3) a second polymer coating layer permeable to the passage of said agent, wherein said second polymer coating layer essentially completely covers said first polymer coating layer and the uncoated portion of the inner core, whereby said agent is able to pass through said second polymer coating layer in a controlled manner wherein said first polymer coating layer and said second polymer coating layer are essentially insoluble and inert in body fluids.
Claim 3
Dependent Claim
20 words
A method for treating a mammalian organism as claimed in claim 1, wherein said second coating layer comprises polyvinyl alcohol.
Claim 4
Dependent Claim
21 words
A method for treating a mammalian organism as claimed in claim 2, wherein said first coating layer comprises ethylene vinyl acetate.
Claim 5
Dependent Claim
20 words
A method for treating a mammalian organism as claimed in claim 3, wherein said effective agent comprises 5-fluorouracil or ganciclovir.
Claim 6
Independent Claim
162 words
A method for treating a mammalian organism for cytomegalovirus retinitis comprising: administering a sustained release drug delivery system to a mammalian organism in need of such treatment, said drug delivery system comprising; (1) an inner core or reservoir comprising an effective amount of ganciclovir effective to obtain a desired local or systemic physiological or pharmacological effect, (2) a first polymer coating layer, said first polymer coating layer essentially impermeable to the passage of said ganciclovir, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first polymer coating layer, and (3) a second polymer coating layer permeable to the passage of said ganciclovir, wherein said second polymer coating layer essentially completely covers said first polymer coating layer and the uncoated portion of the inner core, whereby said ganciclovir is able to pass through said second polymer coating layer in a controlled manner.
Claim 7
Independent Claim
162 words
A method for treating a mammalian organism for cytomegalovirus retinitis comprising: administering a sustained release drug delivery system to a mammalian organism in need of such treatment, said drug delivery system comprising; (1) an inner core or reservoir comprising an effective amount of ganciclovir effective to obtain a desired local or systemic physiological or pharmacological effect, (2) a first polymer coating layer, said first polymer coating layer essentially impermeable to the passage of said ganciclovir, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first polymer coating layer, and (3) a second polymer coating layer permeable to the passage of said ganciclovir, wherein said second polymer coating layer essentially completely covers said first polymer coating layer and the uncoated portion of the inner core, whereby said ganciclovir is able to pass through said second polymer coating layer in a controlled manner.
Claim 8
Independent Claim
207 words
A method for treating a mammalian organism to obtain a desired physiological or pharmacological effect comprising: placing a sustained release drug delivery system in contact with or within an eye of a mammalian organism in need of such treatment, said drug delivery system comprising; (1) an inner core having an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect and an inner polymer coating permeable to the passage of said agent covering at least a portion of said agent, (2) a first polymer coating essentially impermeable to the passage of said agent, said first polymer coating covering at least a portion but not the entire surface area of said inner polymer coating of said inner core, and (3) a second polymer coating permeable to the passage of said agent, wherein said second polymer coating essentially completely covers said first polymer coating and any uncoated portion of the inner core, whereby said agent is able to pass through said second polymer coating, wherein each of the polymers selected to make the device are essentially insoluble and inert in body fluids and compatible with eye tissues, and allowing said agent to pass through said second polymer coating to obtain a desired effect.
Claim 9
Independent Claim
207 words
A method for treating a mammalian organism to obtain a desired physiological or pharmacological effect comprising: placing a sustained release drug delivery system in contact with or within an eye of a mammalian organism in need of such treatment, said drug delivery system comprising; (1) an inner core having an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect and an inner polymer coating permeable to the passage of said agent covering at least a portion of said agent, (2) a first polymer coating essentially impermeable to the passage of said agent, said first polymer coating covering at least a portion but not the entire surface area of said inner polymer coating of said inner core, and (3) a second polymer coating permeable to the passage of said agent, wherein said second polymer coating essentially completely covers said first polymer coating and any uncoated portion of the inner core, whereby said agent is able to pass through said second polymer coating, wherein each of the polymers selected to make the device are essentially insoluble and inert in body fluids and compatible with eye tissues, and allowing said agent to pass through said second polymer coating to obtain a desired effect.
Claim 10
Dependent Claim
22 words
The method for treating a mammalian organism according to claim 6, wherein said inner coating of said inner core comprises polyvinyl alcohol.
Claim 11
Dependent Claim
19 words
The method for treating a mammalian organism according to claim 6, wherein said first coating comprises ethylene vinyl acetate.
Claim 12
Dependent Claim
18 words
The method for treating a mammalian organism according to claim 6, wherein said second coating comprises polyvinyl alcohol.
Claim 13
Dependent Claim
18 words
The method for treating a mammalian organism according to claim 6, wherein said agent is ganciclovir or 5-fluorouracil.
Claim 14
Dependent Claim
44 words
The method for treating a mammalian organism according to claim 6, wherein said inner coating of said inner core comprises polyvinyl alcohol, said first coating comprises ethylene vinyl acetate, said second coating comprises polyvinyl alcohol and said agent is cyclosporin, dexamethasone, 5-fluorouracil or ganciclovir.
Claim 15
Dependent Claim
160 words
A sustained release drug delivery system suitable for placing in contact with or within the eye to provide a desired physiological or pharmacological effect comprising: (1) an inner core having an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect and an inner polymer coating permeable to the passage of said agent covering at least a portion of said agent, (2) a first polymer coating essentially impermeable to the passage of said agent, said first polymer coating covering at least a portion but not the entire surface area of said inner polymer coating of said inner core, and (3) a second polymer coating permeable to the passage of said agent, wherein said second polymer coating essentially completely covers said first polymer coating and any uncoated portion of the inner core, wherein each of the polymers selected to make the device are essentially insoluble and inert in body fluids and compatible with eye tissues.
Claim 16
Dependent Claim
160 words
A sustained release drug delivery system suitable for placing in contact with or within the eye to provide a desired physiological or pharmacological effect comprising: (1) an inner core having an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect and an inner polymer coating permeable to the passage of said agent covering at least a portion of said agent, (2) a first polymer coating essentially impermeable to the passage of said agent, said first polymer coating covering at least a portion but not the entire surface area of said inner polymer coating of said inner core, and (3) a second polymer coating permeable to the passage of said agent, wherein said second polymer coating essentially completely covers said first polymer coating and any uncoated portion of the inner core, wherein each of the polymers selected to make the device are essentially insoluble and inert in body fluids and compatible with eye tissues.
Claim 17
Dependent Claim
27 words
The sustained release drug delivery system suitable for placing in the eye according to claim 12, wherein said inner coating of said inner core comprises polyvinyl alcohol.
Claim 18
Dependent Claim
24 words
The sustained release drug delivery system suitable for placing in the eye according to claim 12, wherein said first coating comprises ethylene vinyl acetate.
Claim 19
Dependent Claim
23 words
The sustained release drug delivery system suitable for placing in the eye according to claim 12, wherein said second coating comprises polyvinyl alcohol.
Claim 20
Independent Claim
149 words
A method for providing controlled and sustained administration of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect comprising: surgically implanting a sustained release drug delivery system at a desired location, said drug delivery system comprising; (1) an inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired physiological or pharmacological effect, (2) a polymer coating layer which is essentially impermeable to the passage of said effective μgent, said impermeable layer covering at least a portion or the inner core, wherein at least a small portion of the inner core is not coated with said impermeable polymer coating layer, and (3) a polymer coating layer which essentially completely covers the inner core and is permeable to the passage of said effective agent whereby said agent is able to pass through said polymer coating layer in a controlled manner.
Claim 21
Independent Claim
149 words
A method for providing controlled and sustained administration of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect comprising: surgically implanting a sustained release drug delivery system at a desired location, said drug delivery system comprising; (1) an inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired physiological or pharmacological effect, (2) a polymer coating layer which is essentially impermeable to the passage of said effective μgent, said impermeable layer covering at least a portion or the inner core, wherein at least a small portion of the inner core is not coated with said impermeable polymer coating layer, and (3) a polymer coating layer which essentially completely covers the inner core and is permeable to the passage of said effective agent whereby said agent is able to pass through said polymer coating layer in a controlled manner.
Claim 22
Dependent Claim
19 words
A method as claimed in claim 16, wherein said device is surgically implanted within the vitreous of the eye.
Claim 23
Dependent Claim
25 words
The sustained release drug delivery system suitable for placing in the eye according to claim 12, wherein said agent is cyclosporin, dexamethasone, 5-fluorouracil or ganciclovir.
Claim 24
Dependent Claim
15 words
A method as claimed in claim 17, wherein said permeable coating layer comprises polyvinyl alcohol.
Claim 25
Dependent Claim
16 words
A method as claimed in claim 18, wherein said impermeable coating layer comprises ethylene vinyl acetate.
Claim 26
Dependent Claim
15 words
A method as claimed in claim 20, wherein said effective agent is ganciclovir or 5-fluorouracil.
Claim 27
Dependent Claim
146 words
A sustained release drug delivery system comprising: (A) an inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect, (B) a first polymer coating layer, said first polymer coating layer impermeable to the passage of said effective agent, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first polymer coating layer, and (C) a second polymer coating layer, said second polymer coating layer permeable to the passage of said effective agent, wherein said second polymer coating layer essentially completely covers the first polymer coating layer and the uncovered portion of the inner core, said first polymer coating layer and said second polymer coating layer being essentially insoluble and inert in body fluids.
Claim 28
Dependent Claim
146 words
A sustained release drug delivery system comprising: (A) an inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect, (B) a first polymer coating layer, said first polymer coating layer impermeable to the passage of said effective agent, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first polymer coating layer, and (C) a second polymer coating layer, said second polymer coating layer permeable to the passage of said effective agent, wherein said second polymer coating layer essentially completely covers the first polymer coating layer and the uncovered portion of the inner core, said first polymer coating layer and said second polymer coating layer being essentially insoluble and inert in body fluids.
Claim 29
Dependent Claim
19 words
A sustained release drug delivery system as claimed in claim 22, wherein said second coating layer comprises polyvinyl alcohol.
Claim 30
Dependent Claim
20 words
A sustained release drug delivery system as claimed in claim 23, wherein said first coating layer comprises ethylene vinyl acetate.
Claim 31
Dependent Claim
19 words
A sustained release drug delivery system as claimed in claim 24, wherein said effective agent is ganciclovir or 5-fluorouracil.
Claim 32
Dependent Claim
31 words
The method for treating a mammalian organism as claimed in claim 1, wherein said drug delivery system is attached to an intraocular lens or the haptic extending from said intraocular lens.
Claim 33
Dependent Claim
47 words
The sustained release drug delivery system suitable for placing in the eye according to claim 12, wherein said inner coating of said inner core comprises polyvinyl alcohol, said first coating comprises ethylene vinyl acetate, said second coating comprises polyvinyl alcohol and said agent is ganciclovir or 5-fluorouracil.
Claim 34
Dependent Claim
36 words
The sustained release drug delivery system according to claim 22, further comprising a polymeric layer between said inner core or reservoir and said impermeable coating, whereby said agent is able to pass through said polymeric layer
Claim 35
Dependent Claim
147 words
A sustained release drug delivery system comprising: (a) in inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect, (b) a first polymer coating layer, said first polymer coating layer impermeable to the passage of said effective agent, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first polymer coating layer, and (c) a second polymer coating layer, said second polymer coating layer permeable to the passage of said effective agent, wherein said second polymer coating layer essentially completely covers the first polymer coating layer and the uncovered portion of the inner core, wherein said sustained drug delivery system is attached to an intraocular lens or the haptic extending from said intraocular lens.
Claim 36
Dependent Claim
147 words
A sustained release drug delivery system comprising: (a) in inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect, (b) a first polymer coating layer, said first polymer coating layer impermeable to the passage of said effective agent, and said first polymer coating layer covering at least a portion of the inner core, wherein at least a small portion of the inner core is not coated with said first polymer coating layer, and (c) a second polymer coating layer, said second polymer coating layer permeable to the passage of said effective agent, wherein said second polymer coating layer essentially completely covers the first polymer coating layer and the uncovered portion of the inner core, wherein said sustained drug delivery system is attached to an intraocular lens or the haptic extending from said intraocular lens.
Claim 37
Dependent Claim
21 words
The sustained drug release delivery system as claimed in claim 29, wherein said effective agent is ganciclovir, 5-fluorouracil, colchicine or dexamethasone.
Claim 38
Dependent Claim
31 words
The method for treating a mammalian organism according to claim 1, wherein said sustained release drug delivery system is placed in contact with or within an eye of said mammalian organism.
Claim 39
Dependent Claim
54 words
The method for treating a mammalian organism according to claim 1, wherein said sustained release drug delivery system further comprises a polymeric layer between said inner core or reservoir and said impermeable coating, whereby said agent is able to pass through said polymeric layer between said inner core or reservoir and said impermeable coating.
Claim 40
Dependent Claim
27 words
The method for treating a mammalian organism according to claim 22, wherein said core consists essentially of said agent or a pharmaceutically acceptable salt of said agent.
Claim 41
Dependent Claim
27 words
The method for treating a mammalian organism according to claim 1, wherein said core consists essentially of said agent or a pharmaceutically acceptable salt of said agent.
Claim 42
Dependent Claim
36 words
The sustained release drug delivery system according to claim 22, wherein said polymers used to fabricate said first and second layer are compatible with eye tissues. between said inner core or reservoir and said impermeable coating.
References Cited (Backward Citations)
US3416530A
Cited
US3896819A
Cited
US3618604A
Cited
US3630200A
Cited
US3632739A
Cited
US3980463A
Cited
US3993071A
Cited
US3916899A
Cited
US4036227A
Cited
US3961628A
Cited
US4135514A
Cited
US4142526A
Cited
US4014335A
Cited
US4034758A
Cited
US3977404A
Cited
US4077407A
Cited
US4014334A
Cited
US4008719A
Cited
US4247498A
Cited
US4111203A
Cited
US4111201A
Cited
US4256108A
Cited
US4519909A
Cited
US4186184A
Cited
US4290426A
Cited
US4200098A
Cited
US4326525A
Cited
US4327725A
Cited
US4730013A
Cited
US4475916A
Cited
US4439196A
Cited
EP0180708A1
Cited
US4519801A
Cited
US4522625A
Cited
US4673405A
Cited
US4627850A
Cited
US4711782A
Cited
US4652441A
Cited
US4777049A
Cited
US4692336A
Cited
US4716031A
Cited
US4615698A
Cited
US4657543A
Cited
US4681755A
Cited
US4927687A
Cited
US4952402A
Cited
US4913906B1
Cited
US4913906A
Cited
US4693886A
Cited
US4609374A
Cited
US4624847A
Cited
US4720384A
Cited
US4898733A
Cited
US4717567A
Cited
US4839177A
Cited
US5141752A
Cited
US4786500A
Cited
US4889720A
Cited
US4861627A
Cited
US4891223A
Cited
US4994273A
Cited
EP0316838A1
Cited
US4832957A
Cited
US4877618A
Cited
US5098443A
Cited
US5028435A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-01-02 | 1998-07-04 | 1999-01-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-01-02 | 2002-07-04 | 2003-01-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-01-02 | 2006-07-04 | 2007-01-03 | $7700.00 | Window Closed / Lapsed |